Home Cart Sign in  
Chemical Structure| 1252608-59-5 Chemical Structure| 1252608-59-5

Structure of GIBH-130
CAS No.: 1252608-59-5

Chemical Structure| 1252608-59-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GIBH-130 can suppress IL-1β secretion via activating microglia with IC50 of 3.4 nM and has effect on neuroinflammation.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GIBH-130

CAS No. :1252608-59-5
Formula : C20H20N6O
M.W : 360.41
SMILES Code : O=C(C1=NN=C(C2=CC=CC=C2)C=C1C)N3CCN(C4=NC=CC=N4)CC3
MDL No. :MFCD31544336
InChI Key :ZTJHTEHADIHZJS-UHFFFAOYSA-N
Pubchem ID :50938773

Safety of GIBH-130

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of GIBH-130

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
microglia IC50 3.4 nM suppressing proinflammatory cytokine production, including IL-1β, TNF-α, and NO Front Neuroanat. 2024 Dec 16;18:1511951

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice PTZ kindling model and KA model Oral 0.25 mg/kg Once daily until the end of the behavior test Inhibiting the release of inflammatory factors by activated microglial cells, it was found that when the inflammatory response mediated by activated microglial cells was inhibited, the mortality of mice with increased intestinal K. pneumoniae abundance during generalized tonic-clonic seizures was significantly increased. Cell Death Discov. 2021 Jul 7;7(1):175
Male C57BL/6 mice 6-hydroxydopamine (6-OHDA) unilateral striatal injection-induced Parkinson's disease model Oral gavage 1 mg/kg Once daily for 7 days Alleviated motor impairment, reduced dopaminergic neuron death, decreased microglia density, restored its morphology, and prevented the increase in pro-inflammatory cytokine levels Front Neuroanat. 2024 Dec 16;18:1511951
CD1 mice Neonatal hypoxic-ischemic brain injury model Intraperitoneally (pre-treatment) or subcutaneously (post-treatment) 1 mg/kg Single dose (pre-treatment or post-treatment at 1, 3, and 6 h) or daily administration for 21 days To evaluate the protective effect of AD-16 on neonatal hypoxic-ischemic brain injury. Results showed that AD-16 significantly reduced brain infarct volume, improved neurobehavioral outcomes, and reduced mortality rate. Neurosci Bull. 2022 Aug;38(8):857-870

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.77mL

0.55mL

0.28mL

13.87mL

2.77mL

1.39mL

27.75mL

5.55mL

2.77mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories